It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic obstructive pulmonary disease (COPD) is a major healthcare problem and an important cause of mortality worldwide, causing 3,23 million deaths in 2019, 90% of COPD deaths in those under the age of 70 in low and middle-income countries according to WHO (World Health Organization). COPD is the third leading cause of death globally, with 24% of patients dying within five years of diagnosis . Smoking is the most common risk factor for COPD, as tobacco [1] smoke contains a large number of toxic substances that are both the cause of COPD and the main factor implicated in the progression of the disease . [2]
This narrative review aims to provide scientific help to healthcare professionals to understand the importance of focusing on smoking cessation amongst patients with COPD as the main treatment method, besides pharmacological therapy. The global burden of COPD mortality must be addressed through efforts to reduce exposure to risk factors, assess individual patient risk, and use treatments that lower mortality. In countries that have adopted comprehensive strategies for prevention and treatment, COPD-related mortality rates have declined. The latest research points out the importance of smoking cessation in the prognosis and quality of life among COPD patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Institute of Pneumophthisiology “Marius Nasta”, Bucharest; AerPur Romania, Bucharest, Romania
2 Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania;; AerPur Romania, Bucharest, Romania
3 National Institute of Pneumophthisiology “Marius Nasta”, Bucharest; “Carol Davila” University of Medicine and Pharmacy, Bucharest; AerPur Romania, Bucharest, Romania
4 National Institute of Pneumophthisiology “Marius Nasta”, Bucharest; “Victor Babeș” University of Medicine and Pharmacy, Timișoara; AerPur Romania, Bucharest, Romania
5 AerPur Romania, Bucharest, Romania
6 National Institute of Pneumophthisiology “Marius Nasta”, Bucharest; “Carol Davila” University of Medicine and Pharmacy, Bucharest